Aprotinin in cardiac surgery: A different point of view

Heart Surgery Forum

Volumn 11, Issue 1, 2008, Pages 9-12

  Immer, Franz F ^a   Jent, Philipp ^a   Englberger, Lars ^a   Stalder, Mario ^a   Gygax, Erich ^a   Carrel, Thierry P ^a   Tevaearai, Hendrik T ^a  

^a BERN UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; CREATINE KINASE; FIBRINOLYTIC AGENT;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTINUOUS INFUSION; CORONARY ARTERY BYPASS GRAFT; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HEART SURGERY; HUMAN; INCIDENCE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; TRANSLUMINAL CORONARY ANGIOPLASTY;

AGED; APROTININ; BLOOD TRANSFUSION; FEMALE; HEALTH STATUS INDICATORS; HUMANS; INCIDENCE; MALE; POSTOPERATIVE COMPLICATIONS; POSTOPERATIVE HEMORRHAGE; PROSPECTIVE STUDIES; SERINE PROTEINASE INHIBITORS;

EID: 39449103278     PISSN: 10983511     EISSN: None     Source Type: Journal    
DOI: 10.1532/HSF98.20071149     Document Type: Article

References (13)

1. Alderman EL, Levy JH, Rich JB, et al. 1998. Analyses of coronary graft patency after aprotinin use: results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE). J Thorac Cardiovasc Surg 116:716-30.
2. Bechtel JF, Prosch J, Sievers HH, Bartels C. 2002. Is the kaolin or celite activated clotting time affected by tranexamic acid? Ann Thorac Surg 74:390-3.
3. Beierlein W, Scheule AM, Dietrich W, Ziemer G. 2005. Forty years of clinical aprotinin use: a review of 124 hypersensitivity reactions. Ann Thorac Surg 79:741-8.
4. Basran S, Frumento RJ, Cohen A, et al. 2006. The association between duration of storage of transfused red blood cells and morbidity and mortality after reoperative cardiac surgery. Anesth Analg 103:15-20.
5. D'Ambra MN, Akins CW, Blackstone EH, et al. 1996. Aprotinin in primary valve replacement and reconstruction: a multi-center, double-blind, placebo-controlled trial. J Thorac Cardiovasc Surg 112:1081-9.
6. Dietrich W, Dilthey G, Spannagel M, Jochum M, Braun SL, Richter JA. 1995. Influence of high-dose aprotinin on anticoagulation, heparin requirement, and celite- and kaolin-activated clotting time in heparin-pretreated patients undergoing open-heart surgery, a double-blind, placebo-controlled study. Anesthesiology 83:679-89.
7. Feindt PR, Walcher S, Volkmer I, et al. 1995. Effects of high-dose aprotinin on renal function in aortocoronary bypass grafting. Ann Thorac Surg 60:1076-80.
8. Ferraris VA, Bridges CR, Anderson RP. 2006. Aprotinin in cardiac surgery. N Engl J Med 354:1953-7.
9. Levy JH, Ramsay JG, Guyton RA. 2006. Aprotinin in cardiac surgery. N Engl J Med 354:1953-7.
10. Levy JH, Pifarre R, Schaff HV, et al. 1995. A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting. Circulation 92:2236-44.
11. Mangano DT, Tudor IC, Dietzel C. 2006. The risk associated with aprotinin in cardiac surgery. N Engl J Med 354:353-65.
12. Sedrakyan A, Treasure T, Elefteriades JA. 2004. Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery a systematic review and meta-analysis of randomized clinical trials. J Thorac Cardiovasc Surg 128:442-8.
13. Sundt TM III, Kouchoukos NT, Saffitz JE, Murphy SF, Wareing TH, Stahl DJ. 1993. Renal dysfunction and intravascular coagulation with aprotinin and hypothermic circulatory arrest. Ann Thorac Surg 55:1418-23.